financetom
Business
financetom
/
Business
/
Tata Sons to gain full control over Air Asia India operations, says report
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tata Sons to gain full control over Air Asia India operations, says report
Dec 25, 2019 2:01 AM

Tata Sons is all set to gain full control over AirAsia India as its Malaysian parent has agreed to amend a controversial brand licensing agreement that gave it control of crucial functions, reported Business Standard.

The development, the report said, comes after Tata Sons and AirAsia Berhad decided to amend a controversial brand licensing agreement that gave the Malaysian firm control over crucial functions of the carrier.

The draft agreement submitted to the aviation ministry by the two groups, the report said, makes it clear that various departments such as sales and distribution, revenue management, network planning, catering and engineering, among others, will now be under the control of AirAsia India thus nullifying the need of prior approval from the Malaysian parent firm.

Further, the report said, Tata has already appointed key members of its group in to the key posts of the carrier. This includes appointment of Sunil Bhaskaran as chief executive of AirAsia India, and the upcoming appointment of Tata Sons president Banmali Agrawala as its chairman.

The 2013 agreement, the report said, gave the Malayasian group strategic power over the carrier as all key decisions were to be approved by it. This in turn had led to controversy in India. The civil aviation regulations in the country make it very clear that the effective control of all jointly held Indian carriers should be in the hands of the Indian firm.

Tata, the report said, owns 51 percent stake in the low-cost carrier while Air Asia controls the remaining 49 percent.

First Published:Dec 25, 2019 11:01 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With Koss Stock?
What's Going On With Koss Stock?
Jul 5, 2024
Koss Corporation ( KOSS ) shares are trading higher Friday on continued interest from retail investors. Here's a look at what's going on.  What To Know: Koss ( KOSS ) shares rocketed more than 250% Wednesday as retail investors circulated a social media post speculating on a possible connection between GameStop Corporation ( GME ) , Chewy, Inc. ( CHWY...
Bionano Genomics to Sell Shares in Direct Offering
Bionano Genomics to Sell Shares in Direct Offering
Jul 5, 2024
10:32 AM EDT, 07/05/2024 (MT Newswires) -- Bionano Genomics ( BNGO ) said Friday it has signed deals to sell about 17.5 million shares at $0.571 apiece to healthcare-focused institutional investors to raise roughly $10 million. The company said it will also issue clinical milestone-linked warrants to the investors, comprising series A warrants to buy up to some 17.5 million...
Welsbach Technology Metals Extends Business Combination Deadline to June 2025
Welsbach Technology Metals Extends Business Combination Deadline to June 2025
Jul 5, 2024
10:23 AM EDT, 07/05/2024 (MT Newswires) -- Welsbach Technology Metals Acquisition ( WTMA ) said Friday it has extended the deadline to complete a business combination by one year to June 30, 2025. The decision was made at a special meeting held on June 28, with approximately 83.5% of shareholders voting, Welsbach Technology said. The extension, approved through amendments to...
What's Going On With Johnson and Johnson Shares Friday?
What's Going On With Johnson and Johnson Shares Friday?
Jul 5, 2024
Johnson and Johnson ( JNJ ) shares are trending on Friday. In the last week, the pharmaceutical company announced positive results from two clinical trials and authorization from Health Canada for RYBREVANT in combination with platinum-based chemotherapy. The Details: The first of the two clinical trials is a Phase 3 study regarding the use of nipocalimab for patients with generalized myasthenia...
Copyright 2023-2026 - www.financetom.com All Rights Reserved